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Abstract
The leishmaniases are a group of diseases caused by different species of the protozoan genus Leishmania and
transmitted by sand fly vectors. They are a major public health problem in almost all continents. There is no
effective control of leishmaniasis and its geographical distribution is expanding in many countries. Great effort has
been made by many scientists to develop a vaccine against leishmaniasis, but, so far, there is still no effective
vaccine against the disease. The only way to generate protective immunity against leishmaniasis in humans is
leishmanization, consisting of the inoculation of live virulent Leishmania as a means to acquire long-lasting
immunity against subsequent infections. At present, all that we know about human immune responses to
Leishmania induced by immunization with killed parasite antigens came from studies with first generation
candidate vaccines (killed promastigote extracts). In the few occasions that the T cell-mediated immune responses
to Leishmania induced by infection and immunization with killed parasite antigens were compared, important
differences were found both in humans and in animals. This review discusses these differences and their relevance
to the development of a vaccine against leishmaniasis, the major problems involved in this task, the recent
prospects for the selection of candidate antigens and the use of attenuated Leishmania as live vaccines.
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Background
The leishmaniases are a group of vector-borne diseases
which pose a major public health problem to many coun-
tries [1]. They are broadly classified as tegumentary (or
cutaneous) and visceral leishmaniasis [2]. The former pro-
duces chronic lesions in the skin and, occasionally, in the
naso-oral mucosa and in severe cases can lead to serious
disfigurement [3]. The latter attacks lymphoid organs rich
in mononuclear phagocytic cells, such as spleen, liver,
bone marrow and lymph nodes and can lead to death if
not treated [4]. It has been estimated that approximately
0.2−0.4 cases of visceral leishmaniasis and 0.7−1.2 million
cases of tegumentary leishmaniasis occur each year glo-
bally, with 20,000−40,000 deaths per year due to visceral
leishmaniasis, but these numbers are probably underesti-
mated. Six countries (India, Bangladesh, Sudan, South
Sudan, Ethiopia and Brazil) account for more than 90 %
visceral leishmaniasis cases. Tegumentary leishmaniasis
shows a wider geographical distribution, with the Ameri-
cas, the Mediterranean basin, and western Asia being the
most affected regions [1].
The infection is caused by different species of the
protozoan genus Leishmania which are transmitted by a
number of different sand fly (Phlebotominae) species to
a variety of mammals, including man [5]. Diversity is
thus the key word for defining the leishmaniases: a
diversity of Leishmania species, sand fly vector species,
eco-epidemiological conditions involved in transmission,
and clinical presentations [6]. Besides that, there is a
high degree of specificity in Leishmania-sand fly interac-
tions [7] in the sense that each vector species typically
transmits only one species of Leishmania [8]. It has been
proposed that this species-specific vector competence is
due to interspecies polymorphisms of lipophosphoglycan
[9], a glycolipid highly abundant on the surface of Leish-
mania promastigotes [10], which mediates the attach-
ment of their flagella to cells of the mid-gut epithelium
of the vector [11]. The ecology and the habits of each
specific vector create the particular conditions for trans-
mission. That is why leishmaniasis can be either a
zoonosis or an anthroponosis [12] and is transmitted to
humans in sylvatic, domestic, and peridomestic cycles in
ecosystems habitats ranging from cities to deserts and
rain forests [5]. Moreover, currently used vector- and
reservoir-targeted control strategies have not been suc-
cessful [13, 14]. As a result of the absence of an effective
control measure, the geographical distribution of leish-
maniasis is continuously expanding to non-endemic
areas, even reaching urban environments [15]. Due to all
of these reasons, it is considered that a vaccine would be
the most comprehensive and cost-effective tool for leish-
maniasis control [16].
In spite of the global efforts on leishmaniasis vaccine
development, there is still no effective vaccine against
the human disease. At present, leishmanization is
considered to be the only way to generate protective
immunity against leishmaniasis in humans. This is an
ancient practice from the Middle East. It consists on the
inoculation of live virulent Leishmania in usually non-
exposed areas of the body to avoid the development of
lesions (and consequent scars) produced by natural in-
fection in conspicuous sites. Its effectiveness is due to
the immune protection conferred by the infection with
Leishmania major against subsequent homologous infec-
tions. It is still used in a few countries, in spite of the
obvious safety concerns [17, 18].
Although important differences between the immune
responses induced by vaccines and infections have been
found both in humans and in animals to various patho-
gens [19–27], there are very few studies addressing
specifically this question with reference to leishmaniasis
(Table 1). The aim of this review is to discuss the
importance of these differences with regard to the devel-
opment of a vaccine against leishmaniasis.
Review
Attempts to develop a vaccine against leishmaniasis
The leishmaniasis vaccine candidates can be broadly clas-
sified as first generation and second generation. First gen-
eration vaccine candidates are crude antigen extracts from
killed promastigotes and have been used with or without
BCG as adjuvant. An advantage of these vaccines is that
they could be manufactured at low technological level and
at relatively low cost in endemic countries [28]. However,
their standardization would be an impossible task. In spite
of the numerous clinical trials performed with these
vaccines, their efficacy has not been clearly demonstrated
[29]. Nevertheless, these trials have provided important
information with regard to the human immune responses
induced by immunization with Leishmania antigens [30].
On the other hand, the second generation candidates are
based on chemically defined antigens and are generally
produced using recombinant DNA technology. This
group includes a variety of approaches for delivery of
defined immunogens: recombinant proteins, DNA, and
genetically engineered organisms, such as vectored vac-
cines and attenuated Leishmania. Since the content of the
so-called second generation vaccines is precisely known,
they tend to be more standardizable.
Challenges for the development of a vaccine against
leishmaniasis
There are important challenges to overcome for the
development of a human leishmaniasis vaccine. The trans-
lation of the knowledge acquired from animal models to
the real-life diseases and the transition from the basic
research laboratory to the clinic has been largely unsuc-
cessful [31]. The reductionist paradigm based on the L.
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major murine model may have played a role in this failure.
Another important problem is that the adaptive immune
response that confers protection against leishmaniasis is T
cell-mediated [32]. According to Zinkernagel, all the
available effective vaccines protect hosts via neutralizing
antibodies (usually targeted to viruses or bacterial toxins),
whereas for infections with intracellular pathogens, such
as mycobacteria or Leishmania, which need T cell-
mediated responses for their control, vaccines are either
not available or not fully successful [33]. Another draw-
back is the absence of a reliable correlate of immune
protection in leishmaniasis [31].
Differences in anti-Leishmania immune responses induced
by infection and immunization with killed parasite
antigen
Studies in the mouse model
In the model of experimental infection of BALB/c mice
with L. major, protective CD4+ T cell clones recognizing
antigens associated with live parasites were generated
[34], in contrast with previously described CD4+ T cell
clones that recognized antigens from killed promas-
tigotes and caused disease exacerbation [35]. More
recently, the differences in the immune responses to live
and killed L. major were addressed experimentally using
BALB/c (susceptible) and C57BL/6 (resistant) mice.
Although live and killed parasites were found to elicit
comparable influx and/or proliferation of cells in the
draining lymph nodes, the early cytokine responses to
them were qualitatively different in both mouse strains.
Cells from mice inoculated with live promastigotes pro-
duced significantly more interferon-gamma (IFN-γ) and
less interleukin (IL)-4 in response to soluble Leishmania
antigen in vitro than those from the mice inoculated
with killed parasites. The use of CpG oligodeoxynucleo-
tides (CpG ODN) as adjuvant changed the response of
C57BL/6 mice injected with killed parasites to a pre-
dominantly IFN-γ response, which was shown to be
Table 1 Differences in immune responses induced by live parasites vs killed parasite antigens in leishmaniasis
Host species Leishmania spp. Experimental design Major differences found Reference
Mouse (C57BL/6
or BALB/c)
L. major Early responses in draining lymph
node cells were assessed after
inoculation of 5 × 106 live or killed
L. major into naive mice
Cells from mice inoculated with killed
parasites produced significantly more
IL-4 and less IFN-γ than those from
mice injected with live parasites
[24]
Mouse (C57BL/6) L. major Mice with healed L. major infections
were compared to mice vaccinated
with autoclaved L. major antigen + CpG
ODN using infected sand fly challenge
Mice immunized with autoclaved
L. major antigen + CpG ODN were
protected against needle injection
of parasites but not against infected
sand fly challenge. On the other hand,
mice that were healed from experimental
L. major infections were highly resistant
to sand fly transmitted infection
[42]
Human L. amazonensis; L, mexicana;
L. guyanensis; L. major (vaccine);
L. braziliensis (infection)
PBMC from subjects immunized with
a killed vaccine composed of five
Leishmania strains and from ACL
patients were stimulated in vitro
with L. braziliensis crude
antigen extract
The majority of the responding cells of
the vaccinated subjects were CD8+
T cells, in contrast to the results of a
group of patients, whose Leishmania
antigen-reactive cells were mainly
CD4+ T cells
[47]
Human L. amazonensis (vaccine);
L. braziliensis (infection)
The expression of Vβ chains of
TCR was assessed in cells from
ACL patients and healthy
volunteers before and
after vaccination
Vaccination led to a broad expansion
of the TCR Vβ repertoire both in CD4+
and in CD8+ T cells. On the other hand,
the patients showed a significant
decrease in the expression of certain
TCRs both in CD4+ and in CD8+ T cells
when compared to healthy controls from
the same leishmaniasis endemic area
[48]
Human L. amazonensis (vaccine);
L. braziliensis (infection)
Cytokine responses of PBMC
from ACL patients and subjects
immunized with a vaccine
composed of killed promastigotes
to La and to the recombinant
protein LACK, both from L.
amazonensis, were compared
The IFN-γ levels stimulated by La were
significantly higher and the levels of
IL-10 significantly lower than those
stimulated by LACK in the patient
group, whereas LACK induced a
significantly higher IFN-γ production
and a significantly lower IL-10 production
compared with those induced by La in
the vaccinated group LACK also induced
a significantly higher frequency of
IFN-γ-producing cells than did La in
the vaccinated group
[49]
Abbreviations: ACL American cutaneous leishmaniasis, CpG ODN CpG oligodeoxynucleotides, IFN-γ Interferon- γ, IL-10 interleukin-10, La whole-cell promastigote
antigen extract, LACK Leishmania homologue of receptors for activated C kinase, PBMC peripheral blood mononuclear cells, TCR T-cell receptors
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protective against a subsequent virulent L. major chal-
lenge. However, the protection obtained with killed para-
sites plus CpG ODN was short-lived in comparison to
that provided by the inoculation of live parasites [24].
In experimental murine leishmaniasis, it is well estab-
lished that the same antigen can induce different kinds
of immune responses, depending on the way that it is
presented to the immune system. In the infection of
BALB/c mice with L. major, the LACK antigen (Leish-
mania homologue of receptors for activated C kinase)
induces an early production of IL-4 which initiates the
development of a disease-promoting T helper type 2
(Th2) response [36], which causes the extreme suscepti-
bility of these mice to this parasite [37]. In contrast,
vaccination with LACK plus IL-12 [38], or with a DNA
vaccine expressing LACK [39], is able to protect the
same susceptible mice against L. major infection.
Another important issue concerning experimental in-
fection is whether it is performed by needle injection or
by sand fly bite. Several studies have shown remarkable
differences between these two kinds of experimental
challenge. It has been shown in Leishmania mexicana-
infected Lutzomyia longipalpis that the transmission of
parasites involves the regurgitation of a plug of promas-
tigote secretory gel (PSG) that blocks the anterior parts
of the midgut, where the metacyclic promastigotes
accumulate. Filamentous proteophosphoglycan, a Leish-
mania-specific glycoprotein, was found to be the major
component of PSG and to be responsible for disease
exacerbation [40]. The same group has shown that
immunization of BALB/c mice with L. mexicana PSG or
with a synthetic vaccine containing the glycans found in
it was able to protect them against challenge by the bites
of infected sand flies but not against needle challenge
[41]. Another interesting study has shown that C57BL/6
mice immunized with autoclaved L. major antigen +
CpG ODN were protected against needle injection of
parasites but not against infected sand fly challenge.
However, mice that were healed from experimental L.
major infections (transmitted by needle injection) were
highly resistant to a subsequent sand fly-transmitted
infection. It was shown by intra-vital microscopy and
flow cytometry analysis that the infected sand fly bite,
but not the needle challenge, resulted in a localized and
sustained neutrophil recruitment at the inoculation site.
Finally, it was possible to promote the efficacy of the
killed vaccine by the removal of neutrophils after the
sand fly challenge [42]. The suppressive effects of neu-
trophils on dendritic cells present in the dermis may be
implicated in the incapacity of killed Leishmania vac-
cines to induce resistance against naturally transmitted
infections [43]. Taken collectively, such findings provide
evidence of the differences between infected sand fly and
needle challenges [41, 42]. Nonetheless, it is noteworthy
that the profile of the immune responses generated by
vaccination with dead antigen is always very different from
that resulting from the infection, regardless whether this
is transmitted by sand fly bite or by needle injection.
Observations in humans
In the case of leishmaniasis, the relevance of studying
the differences between the immune responses induced
by live and killed parasites is obvious because leishmani-
zation is the only effective way to achieve immune
protection against leishmaniasis in humans [17] and so
far this has not been possible with any human leishman-
iasis vaccine [44].
A major challenge to the development of a leishmania-
sis vaccine is the translation of the knowledge obtained
in animal models to human disease [31]. Thus, un-
derstanding the human immune response towards the
vaccine candidate molecules is indispensable for the
development of a safe and effective vaccine. The human
immune responses to defined Leishmania antigens have
been studied almost exclusively in naturally infected
(and sometimes naive) subjects [45]. With the single ex-
ception of the fusion recombinant protein LEISH-F1
(formerly known as Leish-111 F) [46], all that is known
about human immune responses to Leishmania antigens
induced by immunization came from studies with first
generation candidate vaccines [30]. In the very few
human studies in which immunization-induced immune
responses were compared to those found in natural in-
fection, profound differences between them have been
revealed [47–49]. In subjects immunized with a first
generation candidate vaccine made of killed promasti-
gotes of five Leishmania strains, the majority of the cells
responding to Leishmania antigens in vitro were found
to be CD8+ T cells, in contrast to patients with active
American tegumentary leishmaniasis, whose Leishmania-
reactive T cells belonged mainly to the CD4+ phenotype
[47]. A modulation on the TCR Vβ repertoire was found
in American cutaneous leishmaniasis patients, who
showed a significant lower expression of certain TCRs in
both CD4+ and in CD8+ T cells as compared to age and
gender matched healthy controls from the same leishman-
iasis endemic area. On the other hand, immunization of
human volunteers with a candidate vaccine containing
killed Leishmania amazonensis promastigotes, led to a
broad expansion of different Vβ TCRs. The authors con-
cluded that their results indicate that infection with live
parasites or exposure to antigens from killed promasti-
gotes can differentially modulate the TCR Vβ repertoire
[48]. Clear contrasts between the cytokine responses to
Leishmania antigens primed by natural infection and by
immunization with the same vaccine composed of killed
L. amazonensis promastigotes have also been observed in
peripheral blood mononuclear cells stimulated with crude
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whole-cell L. amazonensis promastigote extract (La) or
with the recombinant protein LACK. In the group of
patients with active cutaneous leishmaniasis the IFN-γ
levels induced by stimulation with La were significantly
higher and the levels of IL-10 significantly lower than
those stimulated by LACK. However, LACK induced a
significantly higher IFN-γ production and a significantly
lower IL-10 production compared with those induced by
La in the vaccinated group. LACK also induced a signifi-
cantly higher frequency of IFN-γ-producing cells than did
La in the vaccinated group [49]. The data described above
indicate that immune responses to Leishmania antigens
induced by live and killed parasites in men, as well as in
mice [24, 34, 35, 42], are very different. In spite of the evi-
dence of its importance for the identification of the factors
involved in the generation of protective immunity and for
the selection of potential vaccine candidates, this subject
has been largely overlooked in leishmaniasis research.
Selection of vaccine targets
In 1986, Mosmann et al. [50] identified two types of
murine helper T cell clone characterized by different
cytokine profiles and termed them Th1 and Th2, creat-
ing the so-called Th1/Th2 paradigm. These T helper cell
subsets have found clear functional significance in the
mouse model of L. major infection. While the resistant
strains develop a healing Th1-type response after infec-
tion, the typically susceptible BALB/c mouse shows a
Th2 response that leads to disease progression and even-
tually to death [51]. In this model, the key role played by
IFN-γ and Th1 cells in the control of Leishmania infec-
tion has been clearly demonstrated [51, 52]. However,
the clear-cut dichotomy found in the L. major model
was not observed in the experimental infections of mice
with other Leishmania species, namely those of the
Leishmania donovani and L. mexicana complexes [53].
Nevertheless, this reductionist scheme has guided the
understanding of immunopathology of the leishmaniases
and the selection of candidate antigens for a leishmania-
sis vaccine for several decades [54].
In an interesting review, Campos-Neto [54] reminded
that antigens that stimulate a T helper type 1 (Th1) re-
sponse during the disease or even after cure have shown
no protective effect as a vaccine, while antigens associ-
ated with an early Th2 response have been found to be
protective if a Th1 response to them is generated before
infection. According to him, finding disease-associated
Th2 antigens and inducing a Th1 immune response to
them by vaccination could be a promising approach for
developing a leishmaniasis vaccine [54]. Thus, considering
that the immune responses to the same antigen induced
by infection and immunization are different and some-
times even contrasting [49], trying to find antigens that in-
duce a type 1 response in naturally infected subjects
should not lead to the identification of a candidate antigen
for an effective vaccine.
During coevolution, parasites have learned to inhibit
or to subvert the host immune responses to their own
benefit. Some Leishmania species are very effective in
this regard [55, 56]. Particular parasite molecules play
key roles in this successful adaptation. The expression of
these molecules usually correlates with parasite infectiv-
ity and survival. That is why they are called virulence
factors. At present, virulence factors are considered as
potential drug targets and vaccine candidates for the
control of leishmaniasis [57] and other infectious dis-
eases [58]. A number of them have been identified in
Leishmania spp. [2].
A possible way to identify immunogens with the po-
tential to protect humans against leishmaniasis would be
to compare immune responses of patients with active
disease with those of vaccinated subjects. Using this
strategy, we have found that the LACK antigen induced
a proinflammatory cytokine response in peripheral blood
mononuclear cells from vaccinated subjects, contrasting
with that of cells from patients with active cutaneous
leishmaniasis, which had significantly less IFN-γ and
significantly more IL-10 than the former [49]. Antigens
that are capable to induce regulatory (potentially disease-
promoting) responses [59] in naturally infected patients
and proinflammatory (potentially parasiticidal) [51, 52]
responses in vaccinated subjects may be suitable for
further investigations as candidates for a human vaccine.
Immunological studies on human subjects immunized
with first generation candidate vaccines can be useful
in this regard. It should be reminded that some first
generation candidate vaccines, such as Leishvacin®, have
been shown to be safe [60] and immunogenic [61],
although their efficacy has not been unambiguously
established [62].
One could say that the Leishmania virulence factors
already known have been identified almost accidentally,
but now, following the systems immunology approach
using the high-throughput methods currently available
and with the help of advanced computational methods
and bioinformatics infrastructures [63], the discovery of
new virulence factors can be performed at a larger,
systemic scale. Virulent and avirulent samples of the
same parasite species or strain can be compared in order
to identify differences in expression of multiple genes. In
this sense, a very simple and efficient way to generate
avirulent Leishmania is to keep promastigotes for long
periods in axenic cultures [64].
Another interesting application for the identification
of virulence factors would be the development of thera-
peutic vaccines and immunotherapy strategies. In this
sense, Seifert et al. [65] have shown that a DNA vaccine
candidate was able to increase the efficacy of a single
Mendonça Parasites & Vectors  (2016) 9:492 Page 5 of 9
suboptimal dose of liposomal amphotericin B in L. dono-
vani-infected C57BL/6 mice. This DNA vaccine was
composed of a mixture of five MIDGE-Th1 vectors
encoding different leishmanial antigens. Interestingly, at
least three of these five antigens have been characterized
as virulence factors in Leishmania: kinetoplastid mem-
brane protein-11 and the cysteine proteinases CPA and
CPB [2, 6, 64, 66, 67]. Another therapeutic approach
based on the neutralization of the effect of virulence
factors has been proposed with the use of proteinase
inhibitors for treating leishmaniasis [68].
Live vaccines and concomitant immunity
Taking advantage of the better efficacy of live parasites
to induce long-term protective immune responses as
compared to killed parasite vaccines, the generation of
attenuated parasites through targeted disruption of viru-
lence factor coding genes is a contemporary approach
for leishmaniasis vaccine development that is currently
under intensive study [18]. In spite of the many prob-
lems that need to be circumvented before the efficacy of
live attenuated vaccines can be assessed in clinical trials,
namely safety, genetic stability, lack of transmissibility,
preservation conditions, and limited persistence [69],
this seems to be a promising prospect. Persistence of
parasites is a key issue concerning the employment of
attenuated Leishmania as vaccines. It has been shown
that the sterile cure seen in IL-10-deficient mice [70] is
followed by the loss of immunity to reinfection [71].
Therefore, parasite persistence should be involved in the
long-lasting immunity provided by leishmanization [17,
72]. As far as live Leishmania vaccines are concerned,
this issue needs to be more intensively investigated [73].
To understand why infection protects against reinfec-
tion and immunization with killed vaccines does not, the
key factors for the development of concomitant immun-
ity should be identified. Some light has recently been
shed on this question. New data indicate that the protec-
tion conferred by concomitant immunity relies on the
early presence (within 24 h) of IFN-γ producing CD4+ T
cells, which are either rapidly recruited [74] or resident
in the skin [75]. Peters et al. [74] used C57BL/6 mice
clinically healed but chronically infected with L. major
to demonstrate that concomitant immunity is mediated
by short-lived CD44+CD62L-T-bet+Ly6C+CD4+ effector
T cells that pre-exist secondary challenge and not by
memory cells. According to the authors, these effector T
cells are maintained at high frequencies during chronic
infection via reactivation of central memory CD4+ T
cells and the effector T cells themselves. Thus, the role
of Th1 central memory T cells during chronic infection
may not be to generate effector T cells following second-
ary challenge, but rather, to generate these Ly6C+
effector T cells prior to secondary challenge leading to
effective concomitant immunity. This could be the rea-
son for the failure of non-living vaccines to protect
against Leishmania infections transmitted by sand flies.
In another study, also performed with C57BL/6 mice
clinically healed from L. major infection, skin-resident
CD4+ T cells were found in the skin far from the site of
the primary infection and were able to enhance protec-
tion against a later challenge by producing IFN-γ and
recruiting circulating T cells to the skin in a CXCR3-
dependent manner [75].
Taken together, all these data indicate that the best
way to achieve protective immunity against Leishmania
infection by vaccination should be with live vaccines,
such as attenuated parasites. However, in this case, the
long-time persistence of the parasites in the vaccinated
subjects brings the concern of reversion to the pa-
thogenic phenotype. An alternative would be to use a
vaccination strategy able to generate long-lived memory
CD4+ T cells and to keep the antigenic stimulation by
repeated boosting or long-term antigen depots [74].
Finally, bearing in mind the diversity of the leishmania-
ses as a group of different diseases, it should be also con-
sidered that although resistance to reinfection has been
clearly demonstrated both in the mouse model and in
human leishmaniasis caused by L. major, this might not be
the case in American tegumentary leishmaniasis [76].
Conclusions
Currently, there is no effective measure to control
any form of human leishmaniasis. For this reason, the
geographical distribution of these diseases is expan-
ding in many countries to new areas and even to
cities. The absence of any effective control tool and
the extreme diversity of the epidemiological factors
involved in the transmission have led to the general
opinion that a safe and effective vaccine would be the
most comprehensive and cost-effective way to achieve
leishmaniasis control.
Despite decades of effort by many research groups to
develop a vaccine against leishmaniasis, no effective
vaccine is yet available against human leishmaniasis. The
only recognized way to generate protective immunity
against leishmaniasis in humans is leishmanization,
meaning the deliberate infection with live virulent para-
sites. These facts point to the importance of understand-
ing the differences in the anti-Leishmania immune
responses induced by infection and immunization for
the development of an effective vaccine against leish-
maniasis. In spite of the obvious relevance of this
subject, there are surprisingly few studies addressing this
question. All of them have revealed significant differ-
ences in the immune responses to Leishmania antigens
primed by live parasites and killed parasite antigens in
men and in mice.
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These differences should be considered for the selection
of vaccine candidate antigens. During many million years
of coevolution, parasites have learned how to deliver and
present antigens to the host immune system in such a way
that potentially protective responses are either inhibited
or subverted. That is why trying to find antigens that
induce a protective type 1 response during infection will
not help the discovery of promising vaccine candidates.
Instead, the best vaccine candidates should be the antigens
that promote disease by inducing pathogenic mechanisms
during infection, or virulence factors, provided that a
protective immune response could be induced against
them by immunization protocols before infection. The
concept of systems biology applied to immunology and
the high-throughput techniques, which have been inten-
sively developed over the last two decades, have made
possible the identification of virulence factors in live para-
sites in large scale.
The evidence that live parasites are more able to
induce long-term protective immune responses than
killed antigen vaccines recommends the development
of genetically engineered attenuated Leishmania to be
used as live vaccines. Although this approach seems
promising, there are many safety issues to be addressed
before it can be tested in humans. The need for the
presence of live parasites in order to maintain immun-
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